Optinose Shareholders Reap Benefits as Paratek Acquisition Closes

The chapter has closed for Optinose as a publicly traded company. The specialty pharmaceutical firm was acquired by Paratek Pharmaceuticals in May 2025 and subsequently delisted from the Nasdaq exchange. The transaction delivered significant value to shareholders, marking a lucrative conclusion to their investment.

Paratek Pharmaceuticals structured a deal valued at up to $330 million. Investors received an immediate cash payment of $9 per share, representing a substantial 50% premium over the stock’s price in March 2025. The arrangement, however, included further potential upside through contingent value rights:

• An additional $5 per share is achievable through milestone payments
• $1 per share is payable if XHANCE achieves $150 million in revenue by the end of 2028
• A further... Read more...